Healthcare use among US women aged 45 and older: Total costs and costs for selected postmenopausal health risks

被引:58
作者
Hoerger, TJ
Downs, KE
Lakshmanan, MC
Lindrooth, RC
Plouffe, L
Wendling, B
West, SL
Ohsfeldt, RL
机构
[1] Res Triangle Inst, Ctr Econ Res, Res Triangle Pk, NC 27709 USA
[2] Eli Lilly & Co, Indianapolis, IN 46285 USA
[3] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA
[4] Northwestern Univ, Evanston, IL USA
[5] Indiana Univ, Indianapolis, IN 46204 USA
来源
JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE | 1999年 / 8卷 / 08期
关键词
D O I
10.1089/jwh.1.1999.8.1077
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
The purpose of this study is to estimate the level of healthcare use and costs incurred by postmenopausal women overall and for these selected conditions: cardiovascular disease, osteoporosis, breast cancer, and gynecological cancers. National healthcare survey and discharge data were used to estimate healthcare use by women aged 45 and older. Clinical Classification for Health Policy Research (CCHPR) codes were used to identify patients whose primary diagnosis or procedure corresponded with the selected conditions. National weights were used to estimate resource use. Treatment costs were estimated using cost/charge ratios or the Medicare fee schedule to calculate costs for each individual procedure. Estimated total annual medical care treatment costs for women 45 and older were about $186 billion in 1997 dollars, including about $60.4 billion for cardiovascular disease, $12.9 billion for osteoporosis, and $5.0 billion for breast and gynecological cancers. For each condition, estimated resource use and costs are reported for hospitalization, outpatient, nursing home, and home healthcare services. Resource use and costs are also reported by age and expected source of payment. The economic burden of disease for conditions commonly affecting postmenopausal women is substantial. Prior research establishes that hormone replacement therapy (HRT) may be effective in reducing the burden of disease among women who continue preventive therapy for many years, but few at-risk women do so. New alternatives for prevention, such as selective estrogen receptor modulators (SERMs), may be effective in reducing the burden of disease among postmenopausal women.
引用
收藏
页码:1077 / 1089
页数:13
相关论文
共 25 条
[1]  
*AHA, 1996, HOSP STAT
[2]  
*AHA, 1998, EC COST CARD DIS
[3]  
*AHCPR, 1997, TRENDS PERS HLTH CAR
[4]  
Auerbach Judith, 1995, J HLTH SOCIAL BEHA S, P115
[5]   Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women [J].
Beresford, SAA ;
Weiss, NS ;
Voigt, LF ;
McKnight, B .
LANCET, 1997, 349 (9050) :458-461
[6]  
Bidikov I, 1997, GERIATRICS-US, V52, P28
[7]  
BITTNER V, 1994, J WOMENS HEALTH, V3, P369
[8]   Patient-specific decisions about hormone replacement therapy in postmenopausal women [J].
Col, NF ;
Eckman, MH ;
Karas, RH ;
Pauker, SG ;
Goldberg, RJ ;
Ross, EM ;
Orr, RK ;
Wong, JB .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (14) :1140-1147
[9]   Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer [J].
Colditz, GA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (11) :814-823
[10]   Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women [J].
Delmas, PD ;
Bjarnason, NH ;
Mitlak, BH ;
Ravoux, AC ;
Shah, AS ;
Huster, WJ ;
Draper, M ;
Christiansen, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (23) :1641-1647